Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To explore the real world data of trastuzumab Combined With Trastuzumab And Chemotherapy in China, and to explore the relationship between progression free survival and treatment pattern.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pyrotinib and Trastuzumab group | Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Trastuzumab | Drug | Dual anti-HER2 therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Progression free survival(PFS) | The time from starting pyrotinib until disease progression or death from any cause. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival(OS) | The time from starting pyrotinib until death, regardless of cause. | 1 year |
| Objective Response Rate(ORR) | The proportion of patients with complete response (CR) or partial response (PR) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
HER2 positive Metastatic Breast Cancer
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Zhiyong Yu, PhD | Contact | 86-13355312277 | drzhiyongyu@aliyun.com | |
| Chao Li, MD | Contact | 86-15665851082 | lichao19890305@126.com |
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41858362 | Derived | Zhang L, Li C, Song S, Wang F, Ding T, Liu Z, Jin Y, Yu Z. A real-world comparison study of the efficacy of dual-target first-line rescue treatment of human epidermal growth factor receptor 2 positive advanced breast cancer: trastuzumab combined with pertuzumab versus trastuzumab combined with pyrotinib. Front Oncol. 2026 Mar 4;16:1720851. doi: 10.3389/fonc.2026.1720851. eCollection 2026. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068878 | Trastuzumab |
| C000622954 | pyrotinib |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 year |
| Safety | Number of participants with adverse events which were collected at 6 and 18 months after the start of pyrotinib | 1 year |
| D017437 |
| Skin and Connective Tissue Diseases |
| D007162 |
| Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |